---
title: "TUS-PHARMA: The net profit for the third quarter was 2.3495 million yuan, a year-on-year increase of 146.43%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263277182.md"
description: "TUS-PHARMA announced that its revenue for the third quarter was 82.3783 million yuan, a year-on-year increase of 18.40%; net profit was 2.3495 million yuan, a year-on-year increase of 146.43%. Revenue for the first three quarters was 225 million yuan, a year-on-year increase of 3.97%; net profit loss was 14.8206 million yuan, a year-on-year decrease of 47.91%"
datetime: "2025-10-29T11:34:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263277182.md)
  - [en](https://longbridge.com/en/news/263277182.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263277182.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263277182.md) | [繁體中文](https://longbridge.com/zh-HK/news/263277182.md)


# TUS-PHARMA: The net profit for the third quarter was 2.3495 million yuan, a year-on-year increase of 146.43%

TUS-PHARMA announced that the revenue for the third quarter was 82.3783 million yuan, an increase of 18.40% year-on-year; the net profit was 2.3495 million yuan, an increase of 146.43% year-on-year. The revenue for the first three quarters was 225 million yuan, an increase of 3.97% year-on-year; the net profit loss was 14.8206 million yuan, a decrease of 47.91% year-on-year

### Related Stocks

- [GUHAN-PHARMA (000590.CN)](https://longbridge.com/en/quote/000590.CN.md)

## Related News & Research

- [BYD Fang Cheng Bao launches Tai 3 flash-charging edition, opens Tai 7 EV pre-orders](https://longbridge.com/en/news/279056588.md)
- [Trump to hold news conference Monday prior to Kennedy Center board meeting](https://longbridge.com/en/news/279284985.md)
- [Assessing Skanska (OM:SKA B) Valuation After New US Data Center And Los Angeles Infrastructure Contracts](https://longbridge.com/en/news/278926011.md)
- [Rubio and Japan counterpart talk after Trump Iran coalition call](https://longbridge.com/en/news/279283800.md)
- [Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend](https://longbridge.com/en/news/279032574.md)